ZCMD

SHANGHAI, July 23, 2026 /PRNewswire/ -- Zhongchao Inc ("Zhongchao" or the "Company") (NASDAQ: ZCMD), today announced that it has entered into a definitive agreement with certain investors for the purchase and sale of an aggregate of 4,545,455 of the Company's Class A Ordinary Shares, par value $0.744 per share (the "Shares") (or pre-funded warrants in lieu thereof) at a purchase price of $1.10 per share in a registered direct offering. The purchase price for the pre-funded warrants is identical to the purchase price for Shares, less the exercise price of $ 0.001 per share.

SHANGHAI, June 25, 2026 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a platform-based internet technology company offering services for patients with cancer and other major diseases, today announced that the Company will effectuate a 1-for-3 share consolidation of the Company's ordinary shares of US$0.248 par value each (the "Share Consolidation"). Beginning with the opening of trading on June 29, 2026, the Company's Class A ordinary shares will begin trading on a post-Share Consolidation basis on the Nasdaq Capital Market under the same symbol "ZCMD," but under a new CUSIP number of G9897X149.

SHANGHAI, June 4, 2026 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a platform-based internet technology company offering services for patients with cancer and other major diseases, today announced that the Company will effectuate a 1-for-31 share consolidation of the Company's ordinary shares of US$0.008 par value each (the "Share Consolidation"). Beginning with the opening of trading on June 8, 2026, the Company's Class A ordinary shares will begin trading on a post-Share Consolidation basis on the Nasdaq Capital Market under the same symbol "ZCMD," but under a new CUSIP number of G9897X131.

SHANGHAI, May 29, 2026 /PRNewswire/ -- Zhongchao Inc. ("Zhongchao" or the "Company") (NASDAQ: ZCMD), a platform-based internet technology company offering services for patients with cancer and other major diseases, today announced the pricing of a best efforts public offering with gross proceeds to the Company expected to be approximately $5 million, before deducting placement agent fees and other estimated expenses payable by the Company, excluding the exercise of any warrant offered. The offering is comprised of 9,259,260 units (each a "Unit"), each consisting of one Class A ordinary share of the Company, par value $0.008 per share (the "Class A ordinary shares"), or in lieu thereof, a pre-funded warrant, and one warrant to purchase one Class A ordinary share (each, a "Warrant").